Post-marketing surveillance is still ongoing What we do know from available research and patient reports: Musculoskeletal side effects (which include muscle cramps) were reported in clinical trials, though at lower rates than gastrointestinal effects Patient forums and post-marketing reports suggest cramping occurs in some patients, particularly during the early weeks of treatment The side effect may be dose-related, with potentially higher incidence at higher doses What patients tend to report about the cramping timeline: Experiences vary widely, but patients in online communities and support groups often describe a pattern where: Cramping tends to first appear within the first 1-2 weeks of starting treatment Many find cramps feel most noticeable around weeks 2-3 A gradual improvement is commonly reported around weeks 4-6 By weeks 8-12, many (though not all) patients report their cramping has significantly improved or resolved Keep in mind that your experience may differ considerably from these general observations
Conversely, if blood glucose levels are normal or elevated during episodes of faintness, alternative causes such as dehydration, orthostatic hypotension, or vasovagal responses should be considered
The blood pressure-lowering effect appears to be driven primarily by weight loss (patients in the STEP trials lost 10-15% of body weight), though improvements in insulin sensitivity and vascular function may also contribute
Menopause transition is associated with changes in body composition including an increase in fat mass, a decrease in lean mass, and an increase in abdominal adiposity
